Low-Dose Doxycycline Effective for Lymphocytic Scarring Alopecias
By Lori Solomon HealthDay Reporter
FRIDAY, March 21, 2025 – Relative to high-dose doxycycline, low-dose doxycycline is comparably effective but more tolerable for lymphocytic scarring alopecias, according to a research letter published online March 18 in the Journal of the American Academy of Dermatology.
Carli Needle, from the New York University Grossman School of Medicine in New York City, and colleagues evaluated the efficacy and tolerability of low- (20 mg twice daily [BID], 40 mg daily, and 50 mg daily) versus high-dose (50 mg BID, 100 mg daily, and 100 mg BID) doxycycline for lymphocytic scarring alopecias in a retrospective review. The analysis included 241 adults treated between 2009 and 2023.
The researchers found that high-dose doxycycline was associated with significantly higher rates of adverse effects (AEs), most commonly gastrointestinal symptoms and photosensitivity/rash. One in five (20.4 percent) of high-dose patients and 9.1 percent of low-dose patients reduced/discontinued doxycycline due to AEs. Doxycycline use was associated with improvement in inflammation severity, regardless of dose, when adjusting for the presence of at least one adjunctive anti-inflammatory medication. There was no significant difference seen between the groups for progression of hair loss or improvement in number of scalp symptoms. For patient-reported outcomes, there were no significant differences between dose groups after controlling for adjunctive therapies.
"This study highlights the benefits of low-dose doxycycline for lymphocytic scarring alopecias, showing comparable efficacy and improved tolerability relative to high doses," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Alopecia Areata Associated With Severe Psychosocial Impact
THURSDAY, July 24, 2025 -- Alopecia areata (AA) has a severe psychosocial impact, which is linked to illness perceptions and stigma more strongly than disease severity, according...
Prevalence, Incidence of Eczema Increase With Severity of Alopecia Areata
MONDAY, July 14, 2025 -- Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), according to a study...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.